NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









ChromaGenix

ChromaGenix

Private
Raleigh, North CarolinaHealthcare & Life Scienceshttps://chromagenix.com/

Last Round

Corporate Funding

Apr 22, 2025

Company Overview

ChromaGenix is a biotechnology company that develops and manufactures synthetic affinity ligands and chromatography resins to improve the purification of complex biologics such as gene therapies, vaccines, and antibodies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

affinity chromatographybioprocessingchromatography resindownstream processingbiomanufacturingaffinity ligandsAAV purificationbiologics purificationbiotech consumablesCDMOgene therapy manufacturingviral vector purificationbioprocess optimizationbiotech supply chainlab supplies

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ChromaGenix Comparables

Compare ChromaGenix with similar companies based on industry and business-model similarity.

ChromaGenix comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Repligen Corporation
79%
Danaher
77%
Merck
77%

ChromaGenix Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Corporate FundingApr 22, 2025

Key People

Founding team and executive leadership

Michael Crapanzano

Founder and CEO

Founding Team

ChromaGenix Investors

Notable investors and investment history

ChromaGenix investors
InvestorRounds
BioProcess 360 PartnersCorporate Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 22, 2025

    $35M round led by BioProcess 360 Partners.

ChromaGenix Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ChromaGenix Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ChromaGenix's valuation, stock price, and market status.

Firmographic Details

HeadquartersRaleigh, North Carolina
Employee Range14
Year Founded2025
Last FundingApr 22, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.